2. Chalyj M.E., Ahvlediani N.D., Harchilava R.R. Jerektil’naja disfunkcija. Rossijskie klinicheskie rekomendacii. Urologija. 2017; 2 (Suppl. 2): 20–30. Russian (Чалый М.Е., Ахвледиани Н.Д., Харчилава Р.Р. Эректильная дисфункция. Российские клинические рекомендации. Урология. 2017; 2 (Приложение 2): 20–30).

3. Dean R.C., Lue T.F. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am. 2005;32(4):379–395, v. Doi: 10.1016/j.ucl.2005.08.007.

4. Cho M.C., Paick J.S. Udenafil for the treatment of erectile dysfunction. Ther Clin Risk Manag. 2014;10:341–354. Doi: 10.2147/TCRM.S39727.

5. Pastuszak A.W. Current Diagnosis and Management of Erectile Dysfunction. Curr Sex Health Rep. 2014;6(3):164–176. Doi: 10.1007/s11930-014-0023-9.

6. Lue T.F. Erectile dysfunction. N Engl J Med. 2000;342(24):1802–1813. Doi: 10.1056/NEJM200006153422407.

7. McVary K.T. Erectile dysfunction. New Engl. J. Med. 2007;357:2472–2481. Doi: 10.1056/NEJMcp067261.

8. Yafi F.A., Jenkins L., Albersen M., Corona G., Isidori A.M., Goldfarb S., Maggi M., Nelson C.J., Parish S., Salonia A., Tan R, Mulhall J.P., Hellstrom W.J. Erectile dysfunction. Nat Rev Dis Primers. 2016;2:16003. Doi: 10.1038/nrdp.2016.3.

9. Perelman M.A. The impact of relationship variables on the etiology, diagnosis and treatment of erectile dysfunction. Adv Primary Care Med: Clin Updat. 2007;3:3–6.

10. Porst H., Burnett A., Brock G., Ghanem H., Giuliano F., Glina S., et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10(1):130–171. Doi: 10.1111/jsm.12023.

11. Tsertsvadze A., Fink H.A., Yazdi F., MacDonald R., Bella A.J., Ansari M.T., et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and metaanalysis. Ann Intern Med. 2009;151(9):650–661. Doi: 10.7326/0003-4819-151-9-200911030-00150.

12. Tsertsvadze A., Yazdi F., Fink H.A., et al. Diagnosis and treatment of erectile dysfunction. Vol. 171. Agency for Healthcare Research and Quality (US); Rockville: 2009.

13. JinQiu Yuan, RenJie Zhang, ZuYao Yang, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013;63:902–912. Doi: 10.1016/j.eururo.2013.10.014.

14. Damulin I.V., Esilevskij Ju.M. Jerektil’naja disfunkcija: sovremennoe sostojanie problemy. Urologija, 2014;3:95–101. Russian (Дамулин И.В., Есилевский Ю.М. Эректильная дисфункция: современное состояние проблемы. Урология, 2014;3:95–101).

15. Chen L., Staubli S.E., Schneider M.P., Kessels A.G., Ivic S., Bachmann L.M., Kessler T.M. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis. Eur Urol. 2015;68(4):674–680. Doi: 10.1016/j.eururo.2015.03.031.

16. Fink H.A., Mac Donald R., Rutks I.R. et al. Sildenafil for male erectile dysfunction. Arch. Intern. Med. 2002; 162: 1349–1360. Doi: 10.1001/archinte.162.12.1349.

17. Grigorjan V.A., Gazimiev M.A., Demidko Ju.L., Bajduvaliev A.M. Lekarstvennye formy sildenafila dlja lechenija narushenij jerekcii. Urologija 2018;1:159–162. Russian (Григорян В.А., Газимиев М.А., Демидко Ю.Л., Байдувалиев А.М. Лекарственные формы силденафила для лечения нарушений эрекции. Урология. 2018;1:159–162). Doi: https://dx.doi.org/10.18565/urology.2018.1.159–162.

18. Damle B., Duczynski G., Jeffers B.W., et al. Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects. Clin Ther. 2014;36(2):236–244. Doi: 10.1016/j.clinthera.2013.12.010.

19. Lokshin K.L. Sravnitel’naja harakteristika sildenafila i drugih ingibitorov fosfodijesterazy 5-go tipa v lechenii bol’nyh jerektil’noĭ disfunkcieĭ (obzor literatury). Russkij medicinskiĭ zhurnal. 2013; 18: 936–939. Russian (Локшин К.Л. Сравнительная характеристика силденафила и других ингибиторов фосфодиэстеразы 5-го типа в лечении больных эректильной дисфункцией (обзор литературы). Русский медицинский̆ журнал. 2013;18:936–939).

20. Gamidov S.I., Ovchinnikov R.I., Popova A.Ju., Izhbaev S.H. Ingibitory fosfodijesterazy 5-go tipa v lechenii jerektil’noj disfunkcii: proshloe, nastojashhee i budushhee. Urologija 2017;1:103–108. Russian (Гамидов С.И., Овчинников Р.И., Попова А.Ю., Ижбаев С.Х. Ингибиторы фосфодиэстеразы 5-го типа в лечении эректильной дисфункции: прошлое, настоящее и будущее. Урология. 2017;1:103–108). Doi: https://dx.doi.org/10.18565/urol.2017.1.103-107.

21. Rubio-Aurioles E., Porst H., Kim E.D., Montorsi F., Hackett G., Morales A.M., Stuckey B., Būttner H., West T.M., Huynh N.N., Lenero E., Burns P., Kopernicky V. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med. 2012;9:1418–1429. Doi: 10.1111/j.1743-6109.2012.02667.x.

22. Gacci M., Corona G., Salvi M., Vignozzi L., McVary K.T., Kaplan S.A., et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alphablockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61(5):994–1003. Doi: 10.1016/j.eururo.2012.02.033.

23. Porst H., McVary K.T., Montorsi F. et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur. Urol. 2009;56(4):727–735. Doi: 10.1016/j.eururo.2009.04.033.

24. Volkov A.A., Petrichko M.I., Budnik N.V. Ezhednevnyj priem ingibitorov fosfodijesterazy 5-go tipa ‒ korrekcija jerektil’noj disfunkcii i simptomov nizhnih mochevyh putej u bol’nyh adenomoj predstatel’noj zhelezy. Urologiia 2014;4:64–68. Russian (Волков А.А., Петричко М.И., Будник Н.В. Ежедневный прием ингибиторов фосфодиэстеразы 5-го типа ‒ коррекция эректильной дисфункции и симптомов нижних мочевых путей у больных аденомой предстательной железы. Урология. 2014; 4:64–68).

25. Crowe S.M., Streetman D.S. Vardenafil treatment for erectile dysfunction. Ann Pharmacother. 2004;38(1):77–85. Doi: 10.1345/aph.1D019.

26. Korneev I.A. Levitra® (oral’no dispergiruemaja tabletka) – innovacionnyj preparat dlja lechenija bol’nyh jerektil’noj disfunkciej. Urologija 2013;2:64–68. Russian (Корнеев И.А. Левитра® (орально диспергируемая таблетка) – инновационный препарат для лечения больных эректильной дисфункцией. Урология 2013; 2:106–111).

27. Sanford M. Vardenafil orodispersible tablet. Drugs. 2012;72(1):87–98. Doi: 10.2165/11208270-000000000-00000.

28. Hatzimuratidis et al. EAU Guidelines on Erectile Dysfunction, Premature Ejaculation, Penile Curvature and Priapism, 2019.

29. Kang S.G., Kim J.J. Udenafil: efficacy and tolerability in the management of erectile dysfunction. Ther Adv Urol. 2013;5(2):101–110. Doi: 10.1177/1756287212470019.

30. Paick J.S., Kim S.W., Yang D.Y., et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med. 2008;5(4):946–953. Doi: 10.1111/j.1743-6109.2007.00723.x.

31. Kim B.H., Lim H.S., Chung J.Y., Kim J.R., Lim K.S., Sohn D.R., et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol. 2008;65(6):848–854. Doi: 10.1111/j.1365-2125.2008.03107.x.

32. Corona G., Rastrelli G., Burri A., Jannini E.A., Maggi M. The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis. Expert Opin Drug Saf 2016;15:237–247. Doi: 10.1517/14740338.2016.1130126.

33. Goldstein I., McCullough A.R., Jones L.A., Hellstrom W.J., Bowden C.H., Didonato K., et al. A randomized, double-blind, placebocontrolled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med. 2012;9(4):1122–1133. Doi: 10.1111/j.1743-6109.2011.02629.x.

34. Kyle J.A., Brown D.A., Hill J.K. Avanafil for erectile dysfunction. The Annals of pharmacotherapy. 2013;47(10):1312–1320. Doi: 10.1177/1060028013501989.

35. Glina S., Toscano I., Gomatzky C., de Góes P.M., Júnior A.N., Claro J.F., Pagani E. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med. 2009;6(2):553–557. Doi: 10.1111/j.1743-6109.2008.01079.x.

36. Glina S., Fonseca G.N., Bertero E.B., et al. Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med 2010;7(5):1928–1936. Doi: 10.1111/j.1743-6109.2010.01711.x.

37. Peak T.C., Yafi F.A., Sangkum P., Hellstrom W.J. Emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs. 2015;20(2):263–275. Doi: 10.1517/14728214.2015.1021682.

38. Park H.J., Moon K.H., Lee S.W., Lee W.K., Kam S.C., Lee J.H., Park N.C. Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature. World J Mens Health. 2014;32(1):18–27. Doi: 10.5534/wjmh.2014.32.1.18.

39. Paick J.S., Ahn T.Y., Choi H.K., et al. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008;5(11):2672–2680. Doi: 10.1111/j.1743-6109.2008.00945.x.

40. Lee J.Y., Cho S.Y., Oh C.Y., et al. Efficacy and safety of combination therapy with mirodenafil and alpha1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study. Int J Impot Res 2011;23(6):249–256. Doi: 10.1038/ijir.2011.34.

41. Tashkenbaeva E., Nasirova Z., Ziyadullaev S., Kadirova F. The Role of Biopsychosocial Risk Factors on the Intensification of Unstable Angina. International Journal of Advanced Science and Technology. 2020;29(05):1948–1952.